UBXN11 and neoplasm: Next, we tested the combination of GebR-7b with fulvestrant or palbociclib in vivo and showed a significant decrease in tumor growth upon combination therapies as compared to single agent treatments (Fig. 7d, Supplementary Fig. 14a) without a significant body weight change as compared to SOC alone at the end of treatment (Supplementary Fig. 15a).